Bluelight bl-f home health care

The Bluelight BL-F from Wuhan Wellsee New Energy Industry Co., Ltd. is a low-level laser therapy (LLLT) device marketed for home-based diabetes management and general wellness applications. The unit emits coherent red light typically in the 630-650 nm wavelength range at power densities below 5 mW per diode, a standard parameter for Class IIa medical lasers in the non-invasive therapy category. The BL-F designation indicates a specific model within the manufacturer's Bluelight series, with the F variant likely denoting a fixed-output or home-format configuration rather than clinical-grade variable settings. The device is designed for self-administered nasal or acupoint irradiation, with the supplier stating suitability for all ages and user-friendly operation.

Construction typically involves a semiconductor laser diode array mounted in a handheld or headset-style housing, with rechargeable lithium-ion or mains power supply. Standard industry components include a microcontroller for timed session management, LED status indicators, and automatic shut-off at the programmed interval. The output power and wavelength determine tissue penetration depth, with 650 nm red light penetrating approximately 2-3 mm into soft tissue to stimulate mitochondrial ATP production, a mechanism proposed in photobiomodulation literature. The supplier does not publish specific diode count, output stability data, or mean time between failures, which buyers should request for due diligence.

Target buyers include medical device distributors, pharmacy chains, e-commerce wellness retailers, and clinic procurement officers serving chronic disease management programmes. The device serves both individual consumers seeking home-based adjunctive therapy and institutional buyers integrating LLLT into diabetes care protocols. Common trade terms for Chinese medical device exports are FOB Shanghai or Shenzhen, CIF destination port, or EXW Wuhan with buyer-arranged freight. Payment structures typically involve 30 percent T/T deposit with balance against copy of bill of lading, though terms vary by order volume and buyer credit standing. Buyers must independently verify whether the device holds NMPA registration in China and whether the supplier can provide technical file documentation for EU MDR or FDA 510(k) equivalence assessments in target markets.

Wuhan Wellsee New Energy Industry Co., Ltd. is located at No. 5, F13th, Building No. 5, No. 32-38, Wuhan 42000, Hubei Province, China. The supplier holds an imported tier and harbor trust tier, indicating platform import of externally verified data rather than direct platform audit. The response rate is recorded at 0.00 percent with zero average response hours, suggesting limited or no active engagement through the platform messaging system. The address places the company in Wuhan's commercial district rather than a dedicated medical device manufacturing park, which buyers should note when assessing production capability.

The listing describes the company as offering the Bluelight BL-F for home health care, clinic, and hospital settings, but does not state manufacturing certifications such as ISO 13485, factory floor space, R&D headcount, or OEM/ODM capability. No client references, annual turnover, or years in operation are disclosed. The supplier claims CE and ISO compliance for the device, though certificate numbers, issuing bodies, and valid dates are not provided. Given the medical device classification implications, buyers should request the company's business licence, NMPA registration certificate for the BL-F, and the full technical file including risk management report and clinical evaluation documentation before placing volume orders.